Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Kim, Hwang Phill ^a   Yoon, Young Kwang ^a   Kim, Jin Won ^a   Han, Sae Won ^a   Hur, Hyung Seok ^a   Park, Jinah ^a   Lee, Ju Hee ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Bang, Yung Jue ^a   Kim, Tae You ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEFITINIB; LAPATINIB; THYMIDYLATE SYNTHASE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL NUCLEUS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE INACTIVATION; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DETERMINATION; STOMACH CANCER; ACTIVE TRANSPORT; BIOSYNTHESIS; CANCER TRANSPLANTATION; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 67650128519     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005933     Document Type: Article

References (33)

1. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, et al. (2001) The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1: 85-94.
2. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
3. Zhou Y, Li S, Hu YP, Wang J, Hauser J, et al. (2006) Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res 66: 404-411.
4. Rusnak DW, Affleck K, Cockerill SG, Stubberfield C, Harris R, et al. (2001) The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61: 7196-7203.
5. Kim HP, Han SW, Kim SH, Im SA, Oh DY, et al. (2008) Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 7: 607-615.
6. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, et al. (2007) Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919.
7. Xia W, Liu LH, Ho P, Spector NL (2004) Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23: 646-653.
8. Xia W, Husain I, Liu L, Bacus S, Saini S, et al. (2007) Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67: 1170-1175.
9. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
10. Magne N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, et al. (2003) ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 9: 4735-4742.
11. Okabe T, Okamoto I, Tsukioka S, Uchida J, Iwasa T, et al. (2008) Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced downregulation of thymidylate synthase. Mol Cancer Ther 7: 599-606.
12. Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 Suppl 1: S80-89.
13. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
14. van der Wilt CL, Peters GJ (1994) New targets for pyrimidine antimetabolites in the treatment of solid tumours. 1: Thymidylate synthase. Pharm World Sci 16: 84-103.
15. Eliason JF, Megyeri A (2004) Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 5: 383-388.
16. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, et al. (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412.
17. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nonomura M, et al. (2003) Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res 9: 1453-1460.
18. Nomura T, Nakagawa M, Fujita Y, Hanada T, Mimata H, et al. (2002) Clinical significance of thymidylate synthase expression in bladder cancer. Int J Urol 9: 368-376.
19. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
20. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7: 505-516.
21. Lo HW, Hung MC (2006) Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 94: 184-188.
22. Lin SY, Makino K, Xia W, Matin A, Wen Y, et al. (2001) Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808.
23. Hanada N, Lo HW, Day CP, Pan Y, Nakajima Y, et al. (2006) Co-regulation of B-Myb expression by E2F1 and EGF receptor. Mol Carcinog 45: 10-17.
24. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, et al. (2005) Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589.
25. Wang SC, Lien HC, Xia W, Chen IF, Lo HW, et al. (2004) Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell 6: 251-261.
26. Xie Y, Hung MC (1994) Nuclear localization of p185neu tyrosine kinase and its association with transcriptional transactivation. Biochem Biophys Res Commun 203: 1589-1598.
27. Kim JW, Kim HP, Im SA, Kang S, Hur HS, et al. (2008) The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 272: 296-306.
28. Ku JL, Park JG (2005) Biology of SNU cell lines. Cancer Res Treat 37: 1-19.
29. Lee KW, Kim SG, Kim HP, Kwon E, You J, et al. (2008) Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 68: 1916-1926.
30. Hsu SC, Hung MC (2007) Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 282: 10432-10440.
31. Chen QQ, Chen XY, Jiang YY, Liu J (2005) Identification of novel nuclear localization signal within the ErbB-2 protein. Cell Res 15: 504-510.
32. Gribaudo G, Riera L, Rudge TL, Caposio P, Johnson LF, et al. (2002) Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts. J Gen Virol 83: 2983-2993.
33. Rastogi S, Joshi B, Dasgupta P, Morris M, Wright K, et al. (2006) Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes. Mol Cell Biol 26: 4161-4171.